[Skip to Navigation]
September 1999

Mycophenolate in Psoralen–UV-A Desensitization Therapy for Chronic Actinic Dermatitis

Author Affiliations

Not Available

Arch Dermatol. 1999;135(9):1128-1129. doi:10-1001/pubs.Arch Dermatol.-ISSN-0003-987x-135-9-dlt0999

Chronic actinic dermatitis (CAD) is a persistent eczematous photodermatosis that usually affects elderly people.1 Numerous therapeutic approaches have been tried for CAD; however, only psoralen–UV-A (PUVA) desensitization, cyclosporine, azathioprine, and/or a combination of them have consistently been successful.2-4 Mycophenolate mofetil is an immunosuppressant that has been used primarily to prevent rejection in patients who have undergone renal transplantation.5 Because of its similar efficacy and safer profile, mycophenolate has been used as an attractive alternative to azathioprine in the treatment of immunologically mediated diseases.6 We describe 2 patients with CAD who successfully responded to PUVA desensitization using mycophenolate and low-dose prednisone treatment.

Add or change institution